Implications of personal genomic testing for health behaviors: The case of smoking

PGen Study Group

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Introduction: Direct-to-consumer personal genomic testing has the potential to influence health behaviors, including smoking. Critics of this testing highlight limited evidence to support positive behavioral benefits and caution that genomic results may provide false reassurance, leading to unhealthy behaviors. This study investigates interest in genetic risks of smoking-related diseases and changes in smoking behaviors among genomic testing consumers. Methods: From 2012 to 2013, a longitudinal series of web surveys was conducted. A total of 1464 customers of 23andMe and Pathway Genomics completed a survey prior to viewing genomic test results, of which 1002 participants provided data on smoking behaviors 6 months after receiving results. Results: At baseline, 64% of participants were never smokers, 29% were former smokers, and 7% were current smokers. Most baseline current smokers were very interested in genetic risk results for lung cancer (65%) and heart disease (72%). For lung cancer, this interest was significantly greater than former (50% very interested) and never smokers (37% very interested) (p < .0001). Even though participants were interested in smoking-related disease genetic risks, 96% reported the same smoking status at baseline and 6-month follow-up. Importantly, only 1% (n = 13/916) of former and never smokers became current smokers at 6 months and 22% (n = 14/64) of current smokers reported quitting. Conclusions: Overall, smokers show a high level of interest in genetic risks of smoking-related illnesses. The experience of receiving direct-to-consumer genomic health risks does not appear to have obvious harms related to smoking behaviors, with some potential benefits. Implications: In the setting of ongoing controversy surrounding direct-to-consumer genomic testing, this study provides evidence that consumers are interested in genetic risk results of smokingrelated diseases. Receiving genomic testing results does not lead to smoking initiation among never smokers or reinitiation among former smokers and may be associated with a higher quit rate among current smokers at 6-month follow-up than the general population. These findings ease concerns that direct-to-consumer genomic testing could lead to false reassurance and unhealthy behaviors related to smoking.

Original languageEnglish (US)
Pages (from-to)2273-2277
Number of pages5
JournalNicotine and Tobacco Research
Volume18
Issue number12
DOIs
StatePublished - Jan 1 2016

Fingerprint

Health Behavior
Smoking
Lung Neoplasms
Inborn Genetic Diseases
Genomics
Heart Diseases

All Science Journal Classification (ASJC) codes

  • Public Health, Environmental and Occupational Health

Cite this

@article{88816e9d64cd4c5d91fee164b5a1b245,
title = "Implications of personal genomic testing for health behaviors: The case of smoking",
abstract = "Introduction: Direct-to-consumer personal genomic testing has the potential to influence health behaviors, including smoking. Critics of this testing highlight limited evidence to support positive behavioral benefits and caution that genomic results may provide false reassurance, leading to unhealthy behaviors. This study investigates interest in genetic risks of smoking-related diseases and changes in smoking behaviors among genomic testing consumers. Methods: From 2012 to 2013, a longitudinal series of web surveys was conducted. A total of 1464 customers of 23andMe and Pathway Genomics completed a survey prior to viewing genomic test results, of which 1002 participants provided data on smoking behaviors 6 months after receiving results. Results: At baseline, 64{\%} of participants were never smokers, 29{\%} were former smokers, and 7{\%} were current smokers. Most baseline current smokers were very interested in genetic risk results for lung cancer (65{\%}) and heart disease (72{\%}). For lung cancer, this interest was significantly greater than former (50{\%} very interested) and never smokers (37{\%} very interested) (p < .0001). Even though participants were interested in smoking-related disease genetic risks, 96{\%} reported the same smoking status at baseline and 6-month follow-up. Importantly, only 1{\%} (n = 13/916) of former and never smokers became current smokers at 6 months and 22{\%} (n = 14/64) of current smokers reported quitting. Conclusions: Overall, smokers show a high level of interest in genetic risks of smoking-related illnesses. The experience of receiving direct-to-consumer genomic health risks does not appear to have obvious harms related to smoking behaviors, with some potential benefits. Implications: In the setting of ongoing controversy surrounding direct-to-consumer genomic testing, this study provides evidence that consumers are interested in genetic risk results of smokingrelated diseases. Receiving genomic testing results does not lead to smoking initiation among never smokers or reinitiation among former smokers and may be associated with a higher quit rate among current smokers at 6-month follow-up than the general population. These findings ease concerns that direct-to-consumer genomic testing could lead to false reassurance and unhealthy behaviors related to smoking.",
author = "{PGen Study Group} and Emily Olfson and Sarah Hartz and Carere, {Deanna Alexis} and Green, {Robert C.} and Roberts, {J. Scott} and Bierut, {Laura J.} and Christensen, {Kurt D.} and Helm, {Margaret H.} and Krier, {Joel B.} and Lehmann, {Lisa S.} and Erica Schonman and Peter Kraft and Couper, {Mick P.} and Uhlmann, {Wendy R.} and Le, {Lan Q.} and Ruffin, {Mack T.} and Jenny Ostergren and Kiefer, {Amy K.} and Mountain, {Joanna L.} and Braunstein, {Glenn D.} and Crawford, {Scott D.} and Chen, {Clara A.} and Cupples, {L. Adrienne} and Catharine Wang and Gray, {Stacy W.} and Koenig, {Barbara A.} and Kimberly Kaphingst and Sarah Gollust",
year = "2016",
month = "1",
day = "1",
doi = "10.1093/ntr/ntw168",
language = "English (US)",
volume = "18",
pages = "2273--2277",
journal = "Nicotine and Tobacco Research",
issn = "1462-2203",
publisher = "Oxford University Press",
number = "12",

}

Implications of personal genomic testing for health behaviors : The case of smoking. / PGen Study Group.

In: Nicotine and Tobacco Research, Vol. 18, No. 12, 01.01.2016, p. 2273-2277.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Implications of personal genomic testing for health behaviors

T2 - The case of smoking

AU - PGen Study Group

AU - Olfson, Emily

AU - Hartz, Sarah

AU - Carere, Deanna Alexis

AU - Green, Robert C.

AU - Roberts, J. Scott

AU - Bierut, Laura J.

AU - Christensen, Kurt D.

AU - Helm, Margaret H.

AU - Krier, Joel B.

AU - Lehmann, Lisa S.

AU - Schonman, Erica

AU - Kraft, Peter

AU - Couper, Mick P.

AU - Uhlmann, Wendy R.

AU - Le, Lan Q.

AU - Ruffin, Mack T.

AU - Ostergren, Jenny

AU - Kiefer, Amy K.

AU - Mountain, Joanna L.

AU - Braunstein, Glenn D.

AU - Crawford, Scott D.

AU - Chen, Clara A.

AU - Cupples, L. Adrienne

AU - Wang, Catharine

AU - Gray, Stacy W.

AU - Koenig, Barbara A.

AU - Kaphingst, Kimberly

AU - Gollust, Sarah

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Introduction: Direct-to-consumer personal genomic testing has the potential to influence health behaviors, including smoking. Critics of this testing highlight limited evidence to support positive behavioral benefits and caution that genomic results may provide false reassurance, leading to unhealthy behaviors. This study investigates interest in genetic risks of smoking-related diseases and changes in smoking behaviors among genomic testing consumers. Methods: From 2012 to 2013, a longitudinal series of web surveys was conducted. A total of 1464 customers of 23andMe and Pathway Genomics completed a survey prior to viewing genomic test results, of which 1002 participants provided data on smoking behaviors 6 months after receiving results. Results: At baseline, 64% of participants were never smokers, 29% were former smokers, and 7% were current smokers. Most baseline current smokers were very interested in genetic risk results for lung cancer (65%) and heart disease (72%). For lung cancer, this interest was significantly greater than former (50% very interested) and never smokers (37% very interested) (p < .0001). Even though participants were interested in smoking-related disease genetic risks, 96% reported the same smoking status at baseline and 6-month follow-up. Importantly, only 1% (n = 13/916) of former and never smokers became current smokers at 6 months and 22% (n = 14/64) of current smokers reported quitting. Conclusions: Overall, smokers show a high level of interest in genetic risks of smoking-related illnesses. The experience of receiving direct-to-consumer genomic health risks does not appear to have obvious harms related to smoking behaviors, with some potential benefits. Implications: In the setting of ongoing controversy surrounding direct-to-consumer genomic testing, this study provides evidence that consumers are interested in genetic risk results of smokingrelated diseases. Receiving genomic testing results does not lead to smoking initiation among never smokers or reinitiation among former smokers and may be associated with a higher quit rate among current smokers at 6-month follow-up than the general population. These findings ease concerns that direct-to-consumer genomic testing could lead to false reassurance and unhealthy behaviors related to smoking.

AB - Introduction: Direct-to-consumer personal genomic testing has the potential to influence health behaviors, including smoking. Critics of this testing highlight limited evidence to support positive behavioral benefits and caution that genomic results may provide false reassurance, leading to unhealthy behaviors. This study investigates interest in genetic risks of smoking-related diseases and changes in smoking behaviors among genomic testing consumers. Methods: From 2012 to 2013, a longitudinal series of web surveys was conducted. A total of 1464 customers of 23andMe and Pathway Genomics completed a survey prior to viewing genomic test results, of which 1002 participants provided data on smoking behaviors 6 months after receiving results. Results: At baseline, 64% of participants were never smokers, 29% were former smokers, and 7% were current smokers. Most baseline current smokers were very interested in genetic risk results for lung cancer (65%) and heart disease (72%). For lung cancer, this interest was significantly greater than former (50% very interested) and never smokers (37% very interested) (p < .0001). Even though participants were interested in smoking-related disease genetic risks, 96% reported the same smoking status at baseline and 6-month follow-up. Importantly, only 1% (n = 13/916) of former and never smokers became current smokers at 6 months and 22% (n = 14/64) of current smokers reported quitting. Conclusions: Overall, smokers show a high level of interest in genetic risks of smoking-related illnesses. The experience of receiving direct-to-consumer genomic health risks does not appear to have obvious harms related to smoking behaviors, with some potential benefits. Implications: In the setting of ongoing controversy surrounding direct-to-consumer genomic testing, this study provides evidence that consumers are interested in genetic risk results of smokingrelated diseases. Receiving genomic testing results does not lead to smoking initiation among never smokers or reinitiation among former smokers and may be associated with a higher quit rate among current smokers at 6-month follow-up than the general population. These findings ease concerns that direct-to-consumer genomic testing could lead to false reassurance and unhealthy behaviors related to smoking.

UR - http://www.scopus.com/inward/record.url?scp=85014097541&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014097541&partnerID=8YFLogxK

U2 - 10.1093/ntr/ntw168

DO - 10.1093/ntr/ntw168

M3 - Article

C2 - 27613923

AN - SCOPUS:85014097541

VL - 18

SP - 2273

EP - 2277

JO - Nicotine and Tobacco Research

JF - Nicotine and Tobacco Research

SN - 1462-2203

IS - 12

ER -